Mosapride

Mosapride is a prokinetic medication, meaning a drug that stimulates movement of the gastrointestinal tract, and it belongs to the class of selective 5-HT4 (serotonin) receptor agonists. It is often given as the citrate salt, and one of its metabolites, referred to as M1, additionally blocks the 5-HT3 receptor, a property that contributes to speeding transit through the gut ^[1][3].

Clinically, mosapride is used to relieve the symptoms of several upper-digestive disorders in which the stomach empties too slowly or the gut is oversensitive, including chronic gastritis, gastroesophageal reflux disease and functional dyspepsia, and it has also been studied in irritable bowel syndrome ^[1]. Reviews report that it improves overall symptoms and gastric emptying and performs comparably to several other agents, although at least one controlled trial did not find it clearly better than placebo for functional dyspepsia ^[1]. It has been examined as an add-on to acid-suppressing proton pump inhibitors, where combining it with esomeprazole improved esophageal contraction in patients with reflux disease ^[4].

A defining feature of mosapride is its cardiac safety. An earlier 5-HT4 prokinetic, cisapride, was withdrawn in many markets after it was linked to dangerous heart-rhythm disturbances caused by blockade of a cardiac potassium channel (the hERG channel). Mosapride, by contrast, has little effect on this channel and has not shown the same cardiovascular risk in testing, which is a major reason it remains in use ^[2].

Mosapride is taken by mouth, usually on an empty stomach, and is marketed mainly in Japan and other parts of Asia rather than in the United States or Europe ^[1]. It is generally well tolerated ^[1].

Mosapride is prescription only in the countries where it is sold. It is generally well tolerated, with the most common complaints being diarrhea or loose stools, abdominal pain, dry mouth and headache. Less often it can raise liver enzymes or trigger a rise in eosinophils, so occasional monitoring is reasonable with long use. Its low cardiac risk is a key advantage over older prokinetics, but it should still be used thoughtfully in people with serious liver disease. If symptoms do not improve, an underlying cause should be looked for rather than simply continuing the drug.

Mosapride was developed in Japan by Dainippon Pharmaceutical (now Sumitomo Pharma) as part of a deliberate search for a gastroprokinetic that could accelerate sluggish digestion without the cardiac liabilities of the earlier agent cisapride. Introduced to the Japanese market in the late 1990s under the brand name Gasmotin, it was designed to act with high selectivity at the serotonin 5-HT4 receptor while interacting only weakly with the cardiac hERG potassium channel.

This design goal proved central to its identity, since cisapride was later withdrawn in several markets over arrhythmia concerns that mosapride was engineered to avoid. Over the following decades it became a widely prescribed treatment for functional dyspepsia, chronic gastritis and reflux across Japan, South Korea, China, India and other parts of Asia. It has never gained approval in the United States or the European Union, so most of its clinical evidence base and prescribing tradition remains centered in Asian gastroenterology.

Mosapride enjoys a solid reputation in the regions where it is licensed as a dependable, well-tolerated prokinetic that gently speeds gastric emptying and eases the fullness, bloating and early satiety of functional dyspepsia. Clinicians particularly value its favorable cardiac profile; unlike cisapride, it is not associated with the QT-interval problems that ended its predecessor's career, and gastrointestinal side effects such as loose stools are usually mild.

Researchers have also explored it beyond dyspepsia, including its use to improve bowel recovery and transit in various settings. It is worth noting honestly that comparative meta-analyses place its efficacy in the middle of the prokinetic field rather than at the very top, and that its evidence is concentrated in Asian populations. Even so, its combination of a clear mechanism, decades of real-world use and a reassuring safety record has earned it lasting trust among gastroenterologists.